Skip to content
Disclosery

Wildcat Capital Management, LLC

Follow

13F filer, CIK 1582384, NEW YORK, NY

Wildcat Capital Management, LLC reported $168,307,969 across 6 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-07-18.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001999371-25-009410

Period
2025-06-30
Reported value
$168M
Holdings
6
Top 10 weight
100%
New
0
Sold out
2

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CNTAexited-281,859-$4.05M
KRONOS BIO INCexited-1,297,959-$1.07M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001999371-25-009410, largest first. % of portfolio is the value over $168,307,969, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ULCCFRONTIER GROUP HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 28,061,351 shares; 2024Q4: 28,061,351 shares; 2025Q1: 28,061,351 shares; 2025Q2: 28,061,351 shares 28,061,351$102M60.52%0Timeline
RLXRLX TECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 18,046,195 shares; 2024Q4: 18,046,195 shares; 2025Q1: 18,046,195 shares; 2025Q2: 18,046,195 shares 18,046,195$39.9M23.7%0Timeline
TICTIC SOLUTIONS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,500,000 shares; 2025Q2: 1,500,000 shares 1,500,000$16.6M9.84%0Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 495,606 shares; 2024Q4: 495,606 shares; 2025Q1: 495,606 shares; 2025Q2: 495,606 shares 495,606$6.79M4.03%0Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,920,787 shares; 2024Q4: 2,920,787 shares; 2025Q1: 2,920,787 shares; 2025Q2: 2,920,787 shares 2,920,787$3.12M1.85%0Timeline
SILEXION THERAPEUTICS CORPSILEXION THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 113,428 shares; 2025Q1: 113,428 shares; 2025Q2: 113,428 shares 113,428$91.9K0.05%0

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CNTACENTESSA PHARMACEUTICALS PLC281,859$4.05Mshares
KRONOS BIO INCKRONOS BIO INC1,297,959$1.07Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001999371-25-009410 base2025-07-18acceptance time not in the bulk data set